Combined liver X receptor/peroxisome proliferator-activated receptor γ agonist treatment reduces amyloid β levels and improves behavior in amyloid precursor protein/presenilin 1 mice

Journal of Biological Chemistry

Volumn 290, Issue 35, 2015, Pages 21591-21602

  Skerrett, Rebecca ^a   Pellegrino, Mateus P ^b   Casali, Brad T ^a   Taraboanta, Laura ^a   Landreth, Gary E ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOLOGY; GENES; GLYCOPROTEINS; MAMMALS; TRANSCRIPTION;

AMYLOID PRECURSOR PROTEINS; APOLIPOPROTEIN E (APOE); COGNITIVE DEFICITS; COMBINATION THERAPY; EXTRACELLULAR ACCUMULATIONS; INFLAMMATORY RESPONSE; PEROXISOME PROLIFERATORS; PLASMA TRIGLYCERIDES;

GENE EXPRESSION;

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; PIOGLITAZONE; PRESENILIN 1; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; APOLIPOPROTEIN E; AUTACOID; BENZOIC ACID DERIVATIVE; BENZYLAMINE DERIVATIVE; BIOLOGICAL MARKER; LIVER X RECEPTOR; ORPHAN NUCLEAR RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOE GENE; ARTICLE; BEHAVIOR CHANGE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE; GENE EXPRESSION; HIPPOCAMPUS; MALE; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; AGONISTS; ANIMAL; ANIMAL BEHAVIOR; BLOOD; COGNITIVE DEFECT; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; METABOLISM; PARTICLE SIZE; PATHOLOGY; PROTEIN DEGRADATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; BEHAVIOR, ANIMAL; BENZOATES; BENZYLAMINES; BIOMARKERS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION MEDIATORS; MALE; MICE, TRANSGENIC; MICROGLIA; ORPHAN NUCLEAR RECEPTORS; PARTICLE SIZE; PLAQUE, AMYLOID; PPAR GAMMA; PRESENILIN-1; PROTEOLYSIS; THIAZOLIDINEDIONES; TRANSCRIPTION, GENETIC; TRIGLYCERIDES;

EID: 84940703438     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.652008     Document Type: Article

References (70)

1. Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., and Bateman, R. J. (2010) Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science 330, 1774
2. Wildsmith, K. R., Holley, M., Savage, J. C., Skerrett, R., and Landreth, G. E. (2013) Evidence for impaired amyloid β clearance in Alzheimer's disease. Alzheimers. Res. Ther. 5,1-6
3. Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., Goate, A. M., Bales, K. R., Paul, S. M., Bateman, R. J., and Holtzman, D. M. (2011) Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 3, 89ra57
4. Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., Hansen, J. C., Sullivan, P. M., and Paul, S. M. (2009) Human APOE isoform-dependent effects on brain β-amyloid levels in PDAPP transgenic mice. J. Neurosci. 29, 6771-6779
5. Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., and Zlokovic, B. V. (2008) apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J. Clin. Invest. 118, 4002-4013
6. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., and Pericak-Vance, M. A. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923
7. Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., and Roses, A. D. (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90, 9649-9653
8. Holtzman, D. M., Herz, J., and Bu, G. (2012) Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006312
9. Jiang, Q., Lee, C. Y., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., Richardson, J. C., Smith, J. D., Comery, T. A., Riddell, D., Holtzman, D. M., Tontonoz, P., and Landreth, G. E. (2008) ApoE promotes the proteolytic degradation of Aβ. Neuron 58, 681-693
10. Lee, C. Y., Tse, W., Smith, J. D., and Landreth, G. E. (2012) Apolipoprotein E promotes β-amyloid trafficking and degradation by modulating microglial cholesterol levels. J. Biol. Chem. 287, 2032-2044
11. Koldamova, R. P., Lefterov, I. M., Staufenbiel, M., Wolfe, D., Huang, S., Glorioso, J. C., Walter, M., Roth, M. G., and Lazo, J. S. (2005) The liver X receptor ligand T0901317 decreases amyloid β production in vitro and in a mouse model of Alzheimer's disease. J. Biol. Chem. 280, 4079-4088
12. Wahrle, S. E., Jiang, H., Parsadanian, M., Kim, J., Li, A., Knoten, A., Jain, S., Hirsch-Reinshagen, V., Wellington, C. L., Bales, K. R., Paul, S. M., and Holtzman, D. M. (2008) Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 118, 671-682
13. Donkin, J. J., Stukas, S., Hirsch-Reinshagen, V., Namjoshi, D., Wilkinson, A., May, S., Chan, J., Fan, J., Collins, J., and Wellington, C. L. (2010) ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J. Biol. Chem. 285, 34144-34154
14. Lehmann, J. M., Kliewer, S. A., Moore, L. B., Smith-Oliver, T. A., Oliver, B. B., Su, J. L., Sundseth, S. S., Winegar, D. A., Blanchard, D. E., Spencer, T. A., and Willson, T. M. (1997) Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272, 3137-3140
15. Tall, A. R. (2008) Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J. Intern. Med. 263, 256-273
16. Hong, C., and Tontonoz, P. (2014) Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat. Rev. Drug Discov. 13, 433-444
17. Burns, M. P., Vardanian, L., Pajoohesh-Ganji, A., Wang, L., Cooper, M., Harris, D. C., Duff, K., and Rebeck, G. W. (2006) The effects of ABCA1 on cholesterol efflux and Aβ levels in vitro and in vivo. J. Neurochem. 98, 792-800
18. Riddell, D. R., Zhou, H., Comery, T. A., Kouranova, E., Lo, C. F., Warwick, H. K., Ring, R. H., Kirksey, Y., Aschmies, S., Xu, J., Kubek, K., Hirst, W. D., Gonzales, C., Chen, Y., Murphy, E., Leonard, S., Vasylyev, D., Oganesian, A., Martone, R. L., Pangalos, M. N., Reinhart, P. H., and Jacobsen, J. S. (2007) The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 34, 621-628
19. Lefterov, I., Bookout, A., Wang, Z., Staufenbiel, M., Mangelsdorf, D., and Koldamova, R. (2007) Expression profiling in APP23 mouse brain: inhibition of Aβ amyloidosis and inflammation in response to LXR agonist treatment. Mol. Neurodegener. 2, 20
20. Fitz, N. F., Cronican, A., Pham, T., Fogg, A., Fauq, A. H., Chapman, R., Lefterov, I., and Koldamova, R. (2010) Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. J. Neurosci. 30, 6862-6872
21. Vanmierlo, T., Rutten, K., Dederen, J., Bloks, V. W., van Vark-van der Zee, L. C., Kuipers, F., Kiliaan, A., Blokland, A., Sijbrands, E. J., Steinbusch, H., Prickaerts, J., Lütjohann, D., and Mulder, M. (2011) Liver X receptor activation restores memory in aged AD mice without reducing amyloid. Neurobiol. Aging 32, 1262-1272
22. Wesson, D. W., Borkowski, A. H., Landreth, G. E., Nixon, R. A., Levy, E., and Wilson, D. A. (2011) Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's β-amyloidosis mouse model. J. Neurosci. 31, 15962-15971
23. Terwel, D., Steffensen, K. R., Verghese, P. B., Kummer, M. P., Gustafsson, J.-Å., Holtzman, D. M., and Heneka, M. T. (2011) Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis. J. Neurosci. 31, 7049-7059
24. Cui, W., Sun, Y., Wang, Z., Xu, C., Peng, Y., and Li, R. (2012) Liver X receptor activation attenuates inflammatory response and protects cholinergic neurons in APP/PS1 transgenic mice. Neuroscience 210, 200-210
25. Fitz, N. F., Castranio, E. L., Carter, A. Y., Kodali, R., Lefterov, I., and Koldamova, R. (2014) Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonist. J. Alzheimers. Dis. 41, 535-549
26. Yue, L., and Mazzone, T. (2009) Peroxisome proliferator-activated receptor γ stimulation of adipocyte ApoE gene transcription mediated by the Liver receptor X pathway. J. Biol. Chem. 284, 10453-10461
27. Mandrekar-Colucci, S., Karlo, J. C., and Landreth, G. E. (2012) Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J. Neurosci. 32, 10117-10128
28. Daniel, B., Nagy, G., Hah, N., Horvath, A., Czimmerer, Z., Poliska, S., Gyuris, T., Keirsse, J., Gysemans, C., Van Ginderachter, J. A., Balint, B. L., Evans, R. M., Barta, E., and Nagy, L. (2014) The active enhancer network operated by liganded RXR supports angiogenic activity in macrophages. Genes Dev. 28, 1562-1577
29. Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., Brunden, K. R., Wilson, D. A., and Landreth, G. E. (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506
30. Skerrett, R., Malm, T., and Landreth, G. (2014) Nuclear receptors in neurodegenerative diseases. Neurobiol. Dis. 72, 104-116
31. Heneka, M. T., O'Banion, M. K., Terwel, D., and Kummer, M. P. (2010) Neuroinflammatory processes in Alzheimer's disease. J. Neural Transm. 117, 919-947
32. Hickman, S. E., Allison, E. K., and El Khoury, J. (2008) Microglial dysfunction and defective β-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 28, 8354-8360
33. Mandrekar-Colucci, S., and Landreth, G. E. (2010) Microglia and inflammation in Alzheimer's disease. CNS Neurol. Disord. Drug Targets 9, 156-167
34. Chawla, A. (2010) Control of macrophage activation and function by PPARs. Circ. Res. 106, 1559-1569
35. Chinetti-Gbaguidi, G., and Staels, B. (2011) Macrophage polarization in metabolic disorders: functions and regulation. Curr. Opin. Lipidol. 22, 365-372
36. Yamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M. P., and Heneka, M. T. (2012) PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J. Neurosci. 32, 17321-17331
37. Saijo, K., Crotti, A., and Glass, C. K. (2013) Regulation of microglia activation and deactivation by nuclear receptors. Glia 61, 104-111
38. Zelcer, N., Khanlou, N., Clare, R., Jiang, Q., Reed-Geaghan, E. G., Landreth, G. E., Vinters, H. V., and Tontonoz, P. (2007) Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc. Natl. Acad. Sci. U.S.A. 104, 10601-10606
39. A-Gonzalez, N., Bensinger, S. J., Hong, C., Beceiro, S., Bradley, M. N., Zelcer, N., Deniz, J., Ramirez, C., Díaz, M., Gallardo, G., de Galarreta, C. R., Salazar, J., Lopez, F., Edwards, P., Parks, J., Andujar, M., Tontonoz, P., and Castrillo, A. (2009) Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31, 245-258
40. Ghisletti, S., Huang, W., Ogawa, S., Pascual, G., Lin, M.-E., Willson, T. M., Rosenfeld, M. G., and Glass, C. K. (2007) Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARγ. Mol. Cell 25, 57-70
41. Bensinger, S. J., and Tontonoz, P. (2008) Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454, 470-477
42. Shen, C. L., and Murphy, R. M. (1995) Solvent effects on self-assembly of β-amyloid peptide. Biophys. J. 69, 640-651
43. Hu, J., Liu, C.-C., Chen, X.-F., Zhang, Y.-W., Xu, H., and Bu, G. (2015) Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice. Mol. Neurodegener. 10, 6
44. Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., Citron, M., and Landreth, G. (2003) Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23, 7504-7509
45. Lacombe, P., Mathews, P. M., Schmidt, S. D., Breidert, T., Heneka, M. T., Landreth, G. E., Feinstein, D. L., and Galea, E. (2004) Effect of anti-inflammatory agents on transforming growth factor β over-expressing mouse brains: a model revised. J. Neuroinflammation 1, 11
46. Pedersen, W. A., McMillan, P. J., Kulstad, J. J., Leverenz, J. B., Craft, S., and Haynatzki, G. R. (2006) Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 199, 265-273
47. Toledo, E. M., and Inestrosa, N. C. (2010) Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1ΔE9 mouse model of Alzheimer's disease. Mol. Psychiatry 15, 272-285, 228
48. O'Reilly, J.-A., and Lynch, M. (2011) Rosiglitazone improves spatial memory and decreases insoluble Aβ1-42 in APP/PS1 Mice. J. Neuroimmune Pharmacol. 7, 140-144
49. Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., and Landreth, G. E. (2005) Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453
50. Escribano, L., Simón, A.-M., Gimeno, E., Cuadrado-Tejedor, M., López de Maturana, R., García-Osta, A., Ricobaraza, A., Pérez-Mediavilla, A., Del Río, J., and Frechilla, D. (2010) Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 35, 1593-1604
51. Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., Evert, B. O., Dumitrescu-Ozimek, L., Thal, D. R., Landreth, G., Walter, J., Klockgether, T., van Leuven, F., and Heneka, M. T. (2006) Nonsteroidal anti-inflammatory drugs repress β-secretase gene promoter activity by the activation of PPARγ. Proc. Natl. Acad. Sci. U.S.A. 103, 443-448
52. Searcy, J. L., Phelps, J. T., Pancani, T., Kadish, I., Popovic, J., Anderson, K. L., Beckett, T. L., Murphy, M. P., Chen, K.-C., Blalock, E. M., Landfield, P. W., Porter, N. M., and Thibault, O. (2012) Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. J. Alzheimers. Dis. 30, 943-961
53. Nicolakakis, N., Aboulkassim, T., Ongali, B., Lecrux, C., Fernandes, P., Rosa-Neto, P., Tong, X.-K., and Hamel, E. (2008) Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor γ agonist. J. Neurosci. 28, 9287-9296
54. Papadopoulos, P., Rosa-Neto, P., Rochford, J., and Hamel, E. (2013) Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-β and cerebrovascular pathology. PLoS ONE 8, e68612
55. Denner, L. A., Rodriguez-Rivera, J., Haidacher, S. J., Jahrling, J. B., Carmical, J. R., Hernandez, C. M., Zhao, Y., Sadygov, R. G., Starkey, J. M., Spratt, H., Luxon, B. A., Wood, T. G., and Dineley, K. T. (2012) Cognitive enhancement with rosiglitazone links the hippocampal PPARγ and ERK MAPK signaling pathways. J. Neurosci. 32, 16725-35a
56. Hu, Y., Yang, Y., Yu, Y., Wen, G., Shang, N., Zhuang, W., Lu, D., Zhou, B., Liang, B., Yue, X., Li, F., Du, J., and Bu, X. (2013) Synthesis and identification of new flavonoids targeting liver X receptor β involved pathway as potential facilitators of Aβ clearance with reduced lipid accumulation. J. Med. Chem. 56, 6033-6053
57. 2+ myeloid cells in mouse models of Alzheimer's disease. J. Neurosci. 35, 6532-6543
58. Gosselin, D., and Glass, C. K. (2014) Epigenomics of macrophages. Immunol. Rev. 262, 96-112
59. Masciopinto, F., Di Pietro, N., Corona, C., Bomba, M., Pipino, C., Curcio, M., Di Castelnuovo, A., Ciavardelli, D., Silvestri, E., Canzoniero, L. M., Sekler, I., Pandolfi, A., and Sensi, S. L. (2012) Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice. Cell Death Dis. 3, e448
60. Rodriguez-Rivera, J., Denner, L., and Dineley, K. T. (2011) Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral glucoregulatory status. Behav. Brain Res. 216, 255-261
61. Baranowski, M. (2008) Biological role of liver X receptors. J. Physiol. Pharmacol. 59, 31-55
62. Li, A. C., and Glass, C. K. (2004) PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid Res. 45, 2161-2173
63. Beyer, T. P., Schmidt, R. J., Foxworthy, P., Zhang, Y., Dai, J., Bensch, W. R., Kauffman, R. F., Gao, H., Ryan, T. P., Jiang, X.-C., Karathanasis, S. K., Eacho, P. I., and Cao, G. (2004) Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-α agonist in mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo. J. Pharmacol. Exp. Ther. 309, 861-868
64. Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., and Auwerx, J. (1996) PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15, 5336-5348
65. Evans, R. M., Barish, G. D., and Wang, Y.-X. (2004) PPARs and the complex journey to obesity. Nat. Med. 10, 355-361
66. Miao, B., Zondlo, S., Gibbs, S., Cromley, D., Hosagrahara, V. P., Kirchgessner, T. G., Billheimer, J., and Mukherjee, R. (2004) Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J. Lipid Res. 45, 1410-1417
67. Quinet, E. M., Savio, D. A., Halpern, A. R., Chen, L., Schuster, G. U., Gustafsson, J. A., Basso, M. D., and Nambi, P. (2006) Liver X receptor (LXR)-β regulation in LXRα-deficient mice: implications for therapeutic targeting. Mol. Pharmacol. 70, 1340-1349
68. Kruit, J. K., Plösch, T., Havinga, R., Boverhof, R., Groot, P. H., Groen, A. K., and Kuipers, F. (2005) Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology 128, 147-156
69. van der Hoorn, J., Lindén, D., Lindahl, U., Bekkers, M., Voskuilen, M., Nilsson, R., Oscarsson, J., Lindstedt, E., and Princen, H. (2011) Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE∗3Leiden mice without affecting liver or plasma triglyceride levels. Br. J. Pharmacol. 162, 1553-1563
70. Ye, J. M., Doyle, P. J., Iglesias, M. A., Watson, D. G., Cooney, G. J., and Kraegen, E. W. (2001) Peroxisome proliferator-activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-γ activation. Diabetes 50, 411-417